For the year ending 2025-12-31, SANA had -$55,333K decrease in cash & cash equivalents over the period. -$144,766K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -244,166 |
| Depreciation | 12,750 |
| Stock-based compensation expense | 25,464 |
| Change in the estimated fair value of contingent consideration | 14,750 |
| Change in the estimated fair value of success payment liabilities | 14,682 |
| Non-cash expense for operating lease right-of-use assets | 9,171 |
| Impairment of long-lived assets | 44,611 |
| Other non-cash items, net | 10,976 |
| Prepaid expenses and other assets | -1,165 |
| Operating lease right-of-use assets and liabilities | 2,997 |
| Accounts payable | -3,545 |
| Accrued expenses and other liabilities | -4,737 |
| Net cash used in operating activities | -143,828 |
| Purchases of marketable securities | 87,293 |
| Proceeds from maturities of marketable securities | 46,561 |
| Purchases of property and equipment | 938 |
| Proceeds from disposal of assets | 1,432 |
| Net cash provided by (used in) investing activities | -40,238 |
| Proceeds from employee stock purchase plan and exercise of stock options | 2,676 |
| Proceeds related to common stock financings, net | 126,404 |
| Proceeds (principal payments), net for tenant improvement loan | -347 |
| Net cash provided by financing activities | 128,733 |
| Net decrease in cash, cash equivalents, and restricted cash | -55,333 |
| Cash, cash equivalents, and restricted cash at beginning of period | 131,398 |
| Cash, cash equivalents, and restricted cash at end of period | 76,065 |
Sana Biotechnology, Inc. (SANA)
Sana Biotechnology, Inc. (SANA)